Cardio Diagnostics Epi+Gen CHD Heart Disease Risk Assessment Test

Cardio Diagnostic has launched Epi+Gen CHD, a heart disease risk assessment test. Potential patients fill out a screening questionnaire that is reviewed by a board-certified clinician. If eligible for the test, a sampling kit is sent to the patient's home. After the sample is collected, it is shipped to a partner CLIA-certified lab for processing. After approval by a board-certified pathologist, the results are released to the ordering clinician for review and discussion with the patient. According to Cardio Diagnostics' website, the measures DNA methylation status at three specific loci and genotype at five loci. An artificial intelligence-guided algorithm interprets the results of the DNA methylation contextually with respect to the genetic variation, allowing it to interpret epigenetic signatures that would otherwise be confounded by background genetic variation, the company said.